The APOE4 gene affects 25% of the population and drives 44% of all Alzheimer's cases, creating a $181 billion annual burden in the U.S. alone. With 1.1 billion carriers worldwide facing dramatically ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...